162938-15-0

Basic information

• Product Name: N-methyl-3-[2-(methylsulfanyl)phenoxy]-3-phenylpropan-1-amine
• Synonyms: Benzenepropanamine, N-methyl-gamma-(2-(methylthio)phenoxy)-
• CAS NO: 162938-15-0
• Molecular Formula: C₁₇H₂₁NOS
• Molecular Weight: 287.4197
• Mol File: 162938-15-0.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 434.3°C at 760 mmHg
• Flash Point: 216.5°C
• Density: 1.1g/cm³
• Vapor Pressure: 9.56E-08mmHg at 25°C
• Refractive Index: 1.591
• CAS DataBase Reference: N-methyl-3-[2-(methylsulfanyl)phenoxy]-3-phenylpropan-1-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-methyl-3-[2-(methylsulfanyl)phenoxy]-3-phenylpropan-1-amine(162938-15-0)
• EPA Substance Registry System: N-methyl-3-[2-(methylsulfanyl)phenoxy]-3-phenylpropan-1-amine(162938-15-0)

Safety Data

• Hazardous Substances Data: 162938-15-0(Hazardous Substances Data)

Upstream product

• 222961-69-5 [(R)-3-(2-Methanesulfinyl-phenoxy)-3-phenyl-propyl]-dimethyl-amine 
• 222961-71-9 Dimethyl-[(R)-3-(2-methylsulfanyl-phenoxy)-3-phenyl-propyl]-amine 
• 40116-79-8 (R)-(+)-3-(dimethylamino)-1-phenylpropan-1-ol 
• 130922-30-4 1-fluoro-2-(methylsulfinyl)benzene 
• 139696-88-1 2-chlorophenyl methyl sulfoxide 
• 1073-29-6 2-(methylsulfenyl)phenol 
• 1121-24-0 ortho-mercaptophenol 
• 938435-61-1 (2-((R)-3-chloro-1-phenylpropoxy)phenyl)(methyl)sulfane 
• 74-89-5 methylamine 

Relevant articles and documents

Synthesis and PET evaluation of (R)-[S-methyl-11C] thionisoxetine, a candidate radioligand for imaging brain norepinephrine transporters

Introduction: (R)-3-(2-(methylthio)phenoxy)-N-methyl-3-phenylpropan-1-amine [(R)-thionisoxetine; 1] is a potent inhibitor of the norepinephrine transporter (NET). We aimed to label 1 with carbon-11 (t1/2 = 20.4 min) for evaluation as a radioligand for imaging NET in living brain with positron emission tomography (PET). Methods: Methyl 3-(2-((R)-3-(methylamino)-1- phenylpropoxy)phenylthio)-propanoate (MPPP) and 1 were each prepared from o-hydroxythiophenol in three steps. Treatment of MPPP with potassium t-butoxide and [11C]methyl iodide in tetrahydrofuran gave [5-methyl- 11C]thionisoxetine ([11C]1), which was purified with HPLC. The distribution of radioactivity in brain after intravenous injection of [11C]1 into cynomolgus monkey was followed with PET and the appearance of radiometabolites in plasma monitored with radio-HPLC. Results: [11C]1 was obtained in high yield from [11C]methyl iodide. Of the radioactivity injected into monkey, 2.4% entered brain. Ratios of radioactivity in thalamus, mesencephalon, occipital cortex and caudate to that in cerebellum at 93 min were 1.3, 1.2, 1.2 and 1.1, respectively. The radioactivity in plasma corresponding to unchanged radioligand decreased to 53% at 45 min, with the remainder represented by hydrophilic radiometabolites. Conclusions: MPPP is an effective precursor for 11C-methylation to [11C]1, suggesting that the S-γ-propionic acid methyl ester protecting group may have wider value in the 11C-labeling of aryl methyl sulfides. However, the relatively low ratios of radioactivity to the cerebellum together with an unexpected accumulation of radioactivity in the caudate, makes [11C]1 an unpromising NET radioligand. Copyright

Treatment of conduct disorder

Norepinephrine reuptake inhibitors are used to treat conduct disorder.

Potentiation of pharmaceuticals

The present invention provides a method for producing a potentiating effect on a therapeutic action of an agent which is selected from a serotonin re-uptake inhibitor, a norepinephrine re-uptake inhibitors, both a serotonin and norepinephrine re-uptake inhibitor, and an atypical antidepressant in a warm blooded mammal, which comprises administering to said mammal an effective amount of moxonidine, or a pharmaceutically acceptable salt thereof.